Detail of the clinical trial

Title of the trial Phase II trial to evaluate the efficacy and safety of subcutaneously administered Alemtuzumab (CAMPATH, MabCampath) in patients with previously treated B cell chronic lymphotic leukemia
EudraCT number 2005-005074-69
Protocol number CAM203
Sponsor Genzyme Europe BV, Nizozemí
Indications Hemato-oncology
Diagnosis Chronic lymphocytic leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2007
Date of approval by Institute (SÚKL) 18.04.2007
Date of approval by EC 09.05.2007
Date of initiation CT in ČR
Date of ending CT in ČR 25.01.2010
Notice
Sites Univezitní nem. HK
Heamtoonkologie- Univerzitní nem. Brno-Jihlavská

‹‹ Back to list